The identification of prognostic biomarkers involves extensive research and clinical trials. Techniques such as genomic sequencing, proteomics, and bioinformatics are employed to analyze tumor samples and identify specific genes, proteins, or other molecules associated with cancer progression. Validated biomarkers must demonstrate consistent and reliable results across different study populations.
